報價延遲最少15分鐘:2024/12/23 22:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.48/-6.65
|
|
企業價值
187.04M
|
| 資產負債 |
|
每股賬面淨值
6.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
67.64M
|
|
每股收益
3.80
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |